Rajiv Patni - 12 Jun 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role: EVP, Chief R&D Officer
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 12 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 14 Jun 2023, 16:26:37 UTC
Next filing: 26 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$0	+45,000		$0.000000	45,000	12 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+90,000		$0.000000	90,000	12 Jun 2023	Class A common stock	90,000	$99.12	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent Restricted Stock Units, which vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date.
F2	The option, representing a right to purchase a total of 90,000 Class A shares, become exercisable as to 22,500 on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date.